ClinicalTrials.gg
Not yet recruitingNCT07899411Updated Oct 27, 2026

Evaluation of the Effect of Mental Imagery Training Combined With Modified Constraint-Induced Movement Therapy in Individuals With Multiple Sclerosis

An interventional study of odified Constraint-Induced Movement Therapy + Mental Imagery Training and Modified Constraint-Induced Movement Therapy in Multiple Sclerosis, sponsored by Hacettepe University. Not yet recruiting at 1 site in Turkey (Türkiye). Per ClinicalTrials.gov, last updated 2026-10-27.

Sponsored by Hacettepe University · Not applicable, Interventional, and Treatment

Updated Oct 27, 2026Newly registeredGo to Updates ↓
Phase
Not applicable
Study type
Interventional
Enrollment
14
Allocation
Randomized
Sex
All
01

Study summary

This study aims to investigate the effects of mental imagery training combined with modified constraint-induced movement therapy in individuals with multiple sclerosis. Participants will be randomly assigned to an intervention group receiving mental imagery training combined with modified constraint-induced movement therapy or a control group receiving modified constraint-induced movement therapy alone.

02

Conditions studied

  • Multiple Sclerosis

Browse trials for

Keywords

  • multiple sclerosis
  • Modified Constraint-Induced Movement Therapy
  • Mental Imagery
03

In context

Multiple Sclerosis

3,264 studies on the registry are indexed under Multiple Sclerosis; 659 are open to participants now.

This study's planned enrollment of 14 is below the median of 50 across 2,201 interventional studies indexed under Multiple Sclerosis.

Browse Multiple Sclerosis studies →

Lead sponsor

Hacettepe University is the lead sponsor of 1,007 studies on the registry; 214 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. A definitive diagnosis of multiple sclerosis (MS) by a neurologist according to the McDonald criteria.
  2. Presence of an asymmetric upper extremity motor deficit attributable to MS, determined by calculating the difference in performance time between the extremities using the Nine-Hole Peg Test (9HPT).
  3. Marked non-use of the more affected upper extremity during activities of daily living (Motor Activity Log average item score ≤2.5).
  4. Ability to perform at least 20° of wrist extension starting from full wrist flexion, at least 10° of thumb extension or abduction, and at least 10° of extension at the metacarpophalangeal and interphalangeal joints of the other fingers.
  5. No relapse within the previous 3 months.
  6. Right-hand dominance.
  7. Basic computer skills, including turning the computer on and off, opening and closing the relevant program, and adjusting the volume.

Exclusion criteria

Exclusion Criteria:

  1. A score greater than 1 on the Modified Ashworth Scale (MAS >1) in at least one upper extremity muscle.
  2. Upper extremity pain, defined as a score greater than 4 on the Visual Analog Scale (VAS).
  3. A score below 24 on the (MMSE).
  4. Severe hearing and/or speech impairment.
  5. Presence of an additional neurological, musculoskeletal, or other condition that may affect upper extremity motor function.
  6. Previous receipt of Constraint-Induced Movement Therapy (CIMT).
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
14 participants (estimated)

Study arms

  • Experimental
    Mental Imagery + mCIMT Group

    Participants will receive modified constraint-induced movement therapy combined with mental imagery training.

    Behavioral: odified Constraint-Induced Movement Therapy + Mental Imagery Training

  • Active comparator
    mCIMT Group

    Participants will receive modified constraint-induced movement therapy alone.

    Behavioral: Modified Constraint-Induced Movement Therapy

Interventions

  • Behavioralodified Constraint-Induced Movement Therapy + Mental Imagery Training

    Experimental Group (mCIMT + MI) mCIMT: Modified Constraint-Induced Movement Therapy will be administered throughout the treatment period for 90 minutes per session, 5 days per week, for 3 weeks, for a total of 22.5 hours. In addition, a 30-minute transfer package will be administered 5 days per week for 3 weeks, for a total of 7.5 hours. MI: Mental Imagery Training will be administered throughout the treatment period for 20 minutes per session, 5 days per week, for 3 weeks, for a total of 5 hours. A total of 35 hours of intervention will be administered.

    Also known as: Experimental Group

  • BehavioralModified Constraint-Induced Movement Therapy

    Control Group (mCIMT) Modified Constraint-Induced Movement Therapy will be administered throughout the treatment period for 90 minutes per session, 5 days per week, for 3 weeks, for a total of 22.5 hours. In addition, a 30-minute transfer package will be administered 5 days per week for 3 weeks, for a total of 7.5 hours. A total of 30 hours of intervention will be administered.

    Also known as: Active Comparator

06

What researchers measure

Primary outcomes

  1. Wolf Motor Fonksiyon Testi (WMFT)

    Assessment of upper extremity motor function using the Wolf Motor Function Test (WMFT). The Functional Ability Scale (FAS) of the Wolf Motor Function Test (WMFT) assesses upper extremity functional performance during 15 tasks. Each task is scored on a 6-point scale ranging from 0 to 5, where 0 indicates that the affected upper extremity was not used during the task and 5 indicates normal movement. Higher scores indicate better functional ability.

    Time frame: At baseline, immediately after the 3-week intervention, and at 1-month follow-up.

Secondary outcomes

  1. Nine-Hole Peg Test (9HPT)

    Assessment of fine manual dexterity and upper extremity function. The Nine-Hole Peg Test (9HPT) assesses manual dexterity. The participant is instructed to place nine pegs into nine holes and remove them as quickly as possible. The time required to complete the task is recorded in seconds. Shorter completion times indicate better manual dexterity and upper extremity function. A completion time of less than 18 seconds indicates good fine motor dexterity.

    Time frame: At baseline, immediately after the 3-week intervention

  2. Lafayette Hand Grip Test

    Assessment of hand grip strength. The assessment will be performed with the participant in a seated position, with the shoulder adducted, the elbow flexed to 90 degrees and positioned close to the trunk, and the forearm and wrist in a neutral position.

    Time frame: At baseline, immediately after the 3-week intervention

  3. Nelson Visual Hand Reaction Time Test (NVHRT)

    Assessment of visual hand reaction time. Participants will be seated with their forearms and hands resting on a table. The thumb and index finger will be positioned 8-10 cm above the table, with their upper surfaces parallel to each other. Participants will be instructed to focus on the midpoint of a ruler held between the thumb and index finger. When the ruler is released, the numerical value corresponding to the point at which the participant catches it will be recorded. Reaction time will be calculated using the formula: Reaction time (s) = √(2 × distance (cm) / 980 cm/s²), where distance represents the distance the ruler falls before being caught and 980 cm/s² is the acceleration due to gravity. The test will be repeated three times, and the mean reaction time will be calculated.

    Time frame: At baseline, immediately after the 3-week intervention

  4. Modified Fatigue Impact Scale (MFIS)

    Assessment of the impact of fatigue on daily functioning. The Modified Fatigue Impact Scale (MFIS) consists of 21 items divided into three subscales: physical (9 items), cognitive (10 items), and psychosocial (2 items). The total score ranges from 0 to 84, with higher scores indicating a greater impact of fatigue on daily functioning and a worse outcome.

    Time frame: At baseline, immediately after the 3-week intervention, and at 1-month follow-up.

  5. Functional Independence Measure (FIM)

    Assessment of functional independence. The Functional Independence Measure (FIM) is an 18-item scale designed to assess an individual's level of independence in basic activities of daily living, including physical and cognitive activities. The scale consists of two domains: the motor domain, comprising self-care (6 items), sphincter control (2 items), transfers/mobility (3 items), and locomotion (2 items); and the cognitive domain, comprising communication (2 items) and social cognition (3 items). Each item is scored on a 7-point scale ranging from 1 to 7, with higher scores indicating greater independence and a better functional outcome. The total score ranges from 18 to 126.

    Time frame: At baseline, immediately after the 3-week intervention, and at 1-month follow-up.

  6. Motor Activity Log-28 (MAL-28)

    Assessment of the amount and quality of use of the affected upper extremity in daily activities. The Motor Activity Log-28 (MAL-28) is a questionnaire used to assess the use of the more affected upper extremity in individuals following stroke. It consists of two subscales: the Amount of Use (AOU) scale, which assesses how frequently the more affected upper extremity is used in daily activities, and the Quality of Movement (QOM) scale, which assesses the quality of movement during these activities. Both subscales use a 6-point rating scale ranging from 0 to 5. Higher scores indicate greater use of the more affected upper extremity and better movement quality. The 28-item version has demonstrated validity and reliability.

    Time frame: At baseline, immediately after the 3-week intervention, and at 1-month follow-up.

  7. Treatment Satisfaction Measured Using the Visual Analogue Scale (VAS)

    Treatment satisfaction will be assessed using a Visual Analogue Scale (VAS) immediately after completion of the 3-week intervention. Participants will rate their overall satisfaction with the intervention on a scale ranging from 0 to 10, where 0 indicates no satisfaction and 10 indicates the highest possible satisfaction. Higher scores indicate greater satisfaction with the intervention.

    Time frame: Immediately after the 3-week intervention.

07

Study locations

1 site
  • Kocaeli University Hospital - Department of Neurology
    Köseköy, Kocaeli 41000, Turkey (Türkiye)
    • Gizem Şekercan, PhD Student · Contactgizemsekercan@gmail.com · +90 553 416 81 87
    • Yeliz Şekercan · Contact
    • GİZEM ŞEKERCAN, PhD Student · Sub investigator
    • SİNEM YILMAZ · Sub investigator
    • SENA DESTAN BÜNÜL · Sub investigator
    • HÜSNÜ EFENDİ · Sub investigator
08

References and documents

Individual participant data

Plan to share: No — Individual participant data will not be shared with other researchers. Data will be used solely for the purposes of the present study and will be managed in accordance with applicable ethical and data protection requirements.

No publications or documents are linked to this record.

09

Updates

1 registry update since Sep 25, 2026
Registered
First appeared on the registry. No changes since
Oct 27, 2026
Show all 1 update
  1. Oct 27, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07899411
Responsible party
Gizem Şekercan (Principal Investigator, Hacettepe University) — Principal investigator
First posted
Oct 27, 2026
Start date
Oct 2026 (estimated)
Primary completion
Oct 2027 (estimated)
Completion
Dec 2027 (estimated)
Last update
Oct 27, 2026

Study contacts

Gizem Şekercan, PhD Student
Contact
gizemsekercan@gmail.com
+90 553 416 81 87
Yeliz Salcı
principal investigator · Hacettepe University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion